FT.com / Search

1-10 of 465,540 results for In Re: Pharmastem Therapeutics, Inc.

Sorry, we found no matches with all of your words. Here are the nearest matches with some of the words.

FT Suggests - Try these pages on FT.com

Sort by:

Relevance
Date

March 16, 2009
Astellas drops hostile bid for CV Therapeutics
...takeover bid for biotechnology company CV Therapeutics rather than bidding against a higher...competitor Gilead Sciences. Astellas is in partnership with CV to market Lexiscan...see value for Astellas stockholders in CV Therapeutics at the price level of the sale” to...plans to drop a lawsuit it had filed in Delaware against CV and its directors... By Julie MacIntosh in New York
December 19, 2009
Cancer drug blow for Ark Therapeutics
Shares in Ark Therapeutics plummeted on Friday on news that the...medicines regulators. At one stage in the day’s trading, the shares had lost...Williams, chief financial officer of Ark Therapeutics, who said the company would seek to re-apply for approval of the treatment... By John O’Doherty
January 28, 2009
Astellas in hostile bid for CV Therapeutics
...Astellas first proposed to buy CV Therapeutics for $16 per share in a November 14 letter to its board...but was rebuffed a week later. CV Therapeutics has “declined to engage in any meaningful discussions regarding...CV after those talks stalled. CV Therapeutics posted a narrower loss in its most recent quarter, as sales... By Julie MacIntosh in New York
September 25, 2009
Wall St suffers biggest weekly loss since July
...improvement” in the US housing market in the near future. KB’s shares fell 8...fell 5 per cent to $5.49. Research In Motion, which makes BlackBerry phones, added...s ability to maintain market share in North America. The shares fell 17 per cent to $68.19. Allos Therapeutics erased early gains and was down 3.5... By Samantha Pearson in New York
March 16, 2009
Wall Street on course for fifth day of rises
...put a “buy” rating on its stock in new coverage. Consol Energy outperformed...index was steady at 1,431.42. Shares in CV Therapeutics fell 4.6 per cent to $19.71 after Astellas...television company’s earnings were in line for a sharp rise this year. The... By Kiran Stacey in New York
September 29, 2009
Wall Street slides in choppy trading
...compared with a 1.4 per cent increase in June. Economists polled by Reuters had been expecting prices in the 20-city index to have risen only 0...market economist at Avalon. “But we’re at the end of the quarter and I suspect...stocks also weighed on the Nasdaq. Repros Therapeutics dropped 13.9 per cent to 93 cents after...company’s lead drug, Proellexin, in order to resolve the clinical hold placed... By Samantha Pearson in New York
March 16, 2009
Wall St snaps four-day winning streak
...were led higher by General Electric, in spite of figures released on Monday morning...cent to $9.66. Consol Energy rallied in spite of the falling price of oil, rising...operating costs, making it a bargain. Shares in CV Therapeutics fell 5 per cent to $19.64 after Astellas... By Kiran Stacey in New York
February 16, 2009
Cerepro trials boost Ark Therapeutics
Shares in Ark Therapeutics rose to their highest level in four months on Monday, after French authorities allowed its...allows specially selected patients to receive unlicensed drugs in the event of urgent clinical need. “This is a mechanism that... By John O’Doherty
May 5, 2008
E-therapeutics in consultancy move
...research more cost-effective. E-therapeutics has worked on projects with GlaxoSmithKline...consultancy service will use its patented in-silico technology to analyse drug...University spin-out that floated on Aim in November, E-therapeutics is focused on predictive de-risking...effectively sold themselves, but E-therapeutics would in future make its capabilities more... By Chris Tighe
January 8, 2010
S&P holds steady despite jobs data
...Telecoms stocks were down for the third day in a row, adding to pressure from consumer...Federated Investors, said the weakness in defensive stocks indicated that the market still remained...healthcare reform. Elsewhere, shares in Cytori Therapeutics surged 12 per cent to $7.26 after regulators...whereby a patient’s own fat tissue is re-injected into different parts of the... By Samantha Pearson in New York